Thomas Bumol

Thomas Bumol

Director/Board Member at OMEROS CORPORATION

Net worth: 110 400 $ as of 31/05/2026

72 year
Health Technology
Commercial Services
Consumer Services

Profile

Thomas F.
Bumol
is currently an Independent Director at Omeros Corp.
since 2019, a Director at Revalesio Corp.
since 2020, a Director at Spine BioPharma, Inc., an Independent Director at Tentarix Biotherapeutics LP since 2022, and a Venture Partner at Samsara BioCapital LLC starting in 2026.
Formerly, Dr. Bumol was a Director at PanTheryx, Inc., Executive Director & Executive Vice President at Allen Institute For Immunology from 2018 to 2022, Senior VP-Biotechnology & Autoimmunity Research at Eli Lilly & Co. from 2015 to 2017, President at Applied Molecular Evolution, Inc., and Vice President-Research Technologies & Proteins at Lilly Research Laboratories from 2001 to 2012.
Education includes an undergraduate degree from the University of Michigan in 1975 and a doctorate from the University of Minnesota in 1980.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
18/06/2026 10,000 ( 0.01% ) 110 400 $ 31/05/2026

Thomas Bumol active positions

CompaniesPositionStart
OMEROS CORPORATION Director/Board Member 09/02/2019
Director/Board Member 01/10/2020
Director/Board Member 20/05/2022
Director/Board Member -
Private Equity Investor 01/01/2026

Former positions of Thomas Bumol

CompaniesPositionEnd
Director/Board Member 01/08/2022
ELI LILLY AND COMPANY Chief Tech/Sci/R&D Officer 01/12/2017
Director/Board Member -
Chief Tech/Sci/R&D Officer -
░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░ ░░░░ ░░░░░░░░░ -
See the detail of Thomas Bumol's experience

Training of Thomas Bumol

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

81

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Consumer Services

Consumer Services

Commercial Services

Finance

Commercial Services

Health Technology

Health Technology